Vectura has announced a new US partnership for its VR506, which it describes as “an ICS for the treatment of asthma” and as “clinical stage asthma monotherapy delivered using Vectura’s proprietary technology.” Elsewhere, the company has identified the product as a fluticasone propionate DPI.
According to Vectura, it has signed the new agreement for development and licensing of VR506 with the same unnamed company with which it has already partnered on the VR315 salmeterol/fluticasone DPI (approved as AirFluSal Forspiro in Europe). Vectura recently announced that it had received a milestone payment associated with that deal.
The unnamed partner will take responsibility for development, commercialization, and manufacturing of VR506 and will pay Vectura $4 million initially and up to $8 million in development milestones. Additional development milestones and royalties from US sales are possible.
Vectura CEO Chris Blackwell said, “This is an important step for the development of VR506 for the potentially lucrative US market and it extends the successful collaboration with our established US partner. This provides additional third party validation of the progress we have made to date and is a major endorsement of the potential value of this product.”
Read the Vectura press release.
